Show simple item record

dc.contributor.authorSalloum, Fadi N
dc.contributor.authorTocchetti, Carlo G
dc.contributor.authorAmeri, Pietro
dc.contributor.authorArdehali, Hossein
dc.contributor.authorAsnani, Aarti
dc.contributor.authorde Boer, Rudolf A
dc.contributor.authorBurridge, Paul
dc.contributor.authorCabrera, José-Ángel
dc.contributor.authorde Castro, Javier
dc.contributor.authorCórdoba, Raúl
dc.contributor.authorCosta, Ambra
dc.contributor.authorDent, Susan
dc.contributor.authorEngelbertsen, Daniel
dc.contributor.authorFernández-Velasco, María
dc.contributor.authorFradley, Mike
dc.contributor.authorFuster, José J
dc.contributor.authorGalán-Arriola, Carlos
dc.contributor.authorGarcía-Lunar, Inés
dc.contributor.authorGhigo, Alessandra
dc.contributor.authorGonzález-Neira, Anna 
dc.contributor.authorHirsch, Emilio
dc.contributor.authorIbáñez, Borja 
dc.contributor.authorKitsis, Richard N
dc.contributor.authorKonety, Suma
dc.contributor.authorLyon, Alexander R
dc.contributor.authorMartin, Pilar 
dc.contributor.authorMauro, Adolfo G
dc.contributor.authorMazo Vega, Manuel M
dc.contributor.authorMeijers, Wouter C
dc.contributor.authorNeilan, Tomas G
dc.contributor.authorRassaf, Tienush
dc.contributor.authorRicke-Hoch, Melanie
dc.contributor.authorSepulveda, Pilar
dc.contributor.authorThavendiranathan, Paaladinesh
dc.contributor.authorvan der Meer, Peter
dc.contributor.authorFuster, Valentin
dc.contributor.authorKy, Bonnie
dc.contributor.authorLópez-Fernández, Teresa
dc.date.accessioned2024-05-10T12:07:06Z
dc.date.available2024-05-10T12:07:06Z
dc.date.issued2023-12
dc.identifier.citationJACC CardioOncol. 2023 Sep 27;5(6):715-731.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/19362
dc.description.abstractDespite improvements in cancer survival, cancer therapy-related cardiovascular toxicity has risen to become a prominent clinical challenge. This has led to the growth of the burgeoning field of cardio-oncology, which aims to advance the cardiovascular health of cancer patients and survivors, through actionable and translatable science. In these Global Cardio-Oncology Symposium 2023 scientific symposium proceedings, we present a focused review on the mechanisms that contribute to common cardiovascular toxicities discussed at this meeting, the ongoing international collaborative efforts to improve patient outcomes, and the bidirectional challenges of translating basic research to clinical care. We acknowledge that there are many additional therapies that are of significance but were not topics of discussion at this symposium. We hope that through this symposium-based review we can highlight the knowledge gaps and clinical priorities to inform the design of future studies that aim to prevent and mitigate cardiovascular disease in cancer patients and survivors.es_ES
dc.description.sponsorshipDr Salloum is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Numbers R35HL155651 and R44HL164314, and the American Heart Association Strategically Focused Research Network Award Number 23SFRNPCS1063855. Dr Tocchetti is supported by grants from the Italian Ministry of Health (PNRR-MAD-2022-12376632 and RF-2016- 02362988). Dr Ameri is supported by the European Union - Next Generation EU - NRRP M6C2 - Investment 2.1 “Enhancement and strengthening of biomedical research in the NHS” (Italian Ministry of Health PNRR-MAD-2022-12376632). Dr Ardehali is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Numbers HL127646, HL140973, HL138982, and HL140927. Dr Asnani is supported by R01HL163172, R01HL166541, R01HL157530, and K08HL145019 from the National Institutes of Health/National Heart, Lung, and Blood Institute and by a sponsored research agreement with Genentech. Dr de Boer is supported by the Netherlands Heart Foundation (grants 2017-21, 2017-11, 2018-30, and 2020B005), the Leducq Foundation (Cure-PLaN), and the European Research Council (ERC CoG 818715). Dr Fernández-Velasco is supported by the Carlos III Health Institute (ISCIII) (PI20-01482 and PMP22/00098). Dr Fradley is funded by Medtronic and AstraZeneca. Dr Fuster is supported by grant RYC-2016-20026 from the Spanish Ministerio de Ciencia e Innovación (MICIN/AEI/10.13039/ 501100011033 and “ESF Investing in your future”) and the European Research Area Network on Cardiovascular Diseases CHEMICAL (grant AC19/00133, funded by ISCIII and co-funded by the European Union, ERDF, “A way to make Europe”). Drs Galán-Arriola, García-Lunar, Ibáñez, and Martin and the Centro Nacional de Investigaciones Cardiovasculares (CNIC) are supported by the ISCIII, the Ministry of Science and Innovation, and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033). Dr Ibáñez is supported by a European Research Council grant (ERC-CoG 819775). The RESILIENCE project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 945118. Dr Kitsis is supported by the national Heart, Lung, and Blood Institute of the National Institutes of Health under Award Numbers R01HL159062, R01HL157319, R01HL164772, and DOD PR191593. Dr Martin is supported by MCIN-ISCIII-Fondo de Investigación Sanitaria (PI22/01759; PMPTA22/00090-BIOCARDIOTOX) and the Comunidad de Madrid (P2022/BMD-7209-INTEGRAMUNE-CM). Dr Mauro is supported by T32HL149645. Dr Mazo Vega is supported by European Union’s H2020 Program under grant agreement No 874827 (BRAVd) and the Ministerio de Ciencia e Innovación CARDIOPRINT (PLEC2021- 008127). Dr Neilan is supported by a gift from A. Curt Greer and Pamela Kohlberg and from Christina and Paul Kazilionis, the Michael and Kathryn Park Endowed Chair in Cardiology, and a Hassenfeld Scholar Award, and is supported by additional grant funding from the National Institutes of Health/National Heart, Lung, and Blood Institute under Award Numbers R01HL137562 and K24HL150238. Dr Rassaf is supported by the German Research Foundation Lower Saxony (DFG RA969/12-1), Ministry of Science and Culture REBIRTH I/II (ZN3440), and Stiftung Gerdes. Dr Ricke-Hoch is supported by the Lower Saxony Ministry of Science and Culture REBIRTH I/II (ZN3440) and Stiftung Gerdes. Dr van der Meer is supported by a grant from the European Research Council (ERC CoG 101045236, DISSECT-HF). Dr Thavendiranathan is supported by a Tier II Canada Research Chair in Cardiooncology (950-232646). Dr Ky is supported by National Institutes of Health grants R01 HL148272, R01 HL152707, R34 HL146927, R21 HL152148, R21HL157886, and K24 HL167127 and American Heart Association Strategically Focused Research Network Awards 849569 and 869105. Dr Sepulveda is supported by ISCIII (PMPTA2022/00011). Drs Ghigo, Lyon, Ibáñez, Hirsch, Ricke-Hoch, and Rassaf are supported by the Leducq Foundation Transatlantic Networks of Excellence (19CVD02). Dr Salloum has received consulting fees from Ring Therapeutics and funding from Novartis Pharmaceuticals, not related to this work; and served on the advisory board for NovoMedix, LLC, in cardio-oncology but not directly related to this work. Dr Tocchetti has received honoraria or consultation fees from VivaLyfe, Univers Formazione, Solaris, Summeet, AstraZeneca, and Myocardial Solutions; has received funding from Amgen and MSD, outside the submitted work; and is listed as an inventor of 2 patents related to heart failure. Dr Ameri has received speaker and/or advisor fees from AstraZeneca, Boehringer Ingelheim, Bayer, Novartis, Daiichi Sankyo, Janssen, and MSD, all outside the submitted work. Dr Asnani has served as a consultant or advisory board member for Sanofi, AstraZeneca, Cytokinetics, and OncLive; served as the principal investigator of a sponsored research agreement with Genentech; and received honoraria from UpToDate. Dr de Boer has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals GmbH, Ionis Pharmaceuticals, Novo Nordisk, and Roche; and served as a speaker for Abbott, AstraZeneca, Bayer, Bristol Myers Squibb, Novartis, and Roche. Dr Fradley has served as a consultant for AbbVie, AstraZeneca, Johnson and Johnson, Pfizer/Myovant, and Zoll. Drs Ghigo and Hirsch are co-founders and shareholders of Kither Biotech, a pharmaceutical company focused on the development of PI3K inhibitors for airway diseases not in conflict with the content of this paper. Dr Kitsis is a founder of ASPIDA Therapeutics Inc. Dr Lyon has received speaker, advisory board, or consulting fees and/or research grants from Pfizer, Novartis, Servier, AstraZeneca, Bristol Myers Squibb, GSK, Amgen, Takeda, Roche, Janssen-Cilag Ltd, Astellas Pharma, Clinigen Group, Eli Lilly, Eisai Ltd, Ferring Pharmaceuticals, Boehringer Ingelheim, Akcea Therapeutics, Myocardial Solutions, iOWNA Health, and Heartfelt Technologies Ltd. Dr Neilan has served as a consultant for and received fees from Bristol Myers Squibb, Genentech, CRC Oncology, Roche, Sanofi, and Parexel Imaging Pharmaceuticals; and received grant funding from AstraZeneca and Bristol Myers Squibb related to immune therapies. Dr Rassaf has received honoraria, lecture fees, and grant support from Edwards Lifesciences, AstraZeneca, Bayer, Novartis, Berlin Chemie, Daiichi Sankyo, Boehringer Ingelheim, Novo Nordisk, Cardiac Dimensions, and Pfizer, all unrelated to this work. Dr Thavendiranathan’s institution has received speaker honoraria or consultation fees from Amgen, Novartis, Boehringer Ingelheim, and Takeda. Dr van der Meer has received consulting fees and/or grants from Novartis, Pharmacosmos, Vifor Pharma, AstraZeneca, Pfizer, Pharma Nord, BridgeBio, Novo Nordisk, Boehringer Ingelheim, and Ionis. Dr Ky has received honoraria or grants from Pfizer; and honoraria from Roche, Bristol Myers Squibb, and AstraZeneca. Dr López-Fernández has received speaker fees from Philips, Janssen, Daichi Sankyo, Myocardial Solutions, AstraZeneca, Beigene, and Bayer, not related to the current work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.es_ES
dc.language.isoenges_ES
dc.publisherElsevier es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titlePriorities in Cardio-Oncology Basic and Translational Science: GCOS 2023 Symposium Proceedings: JACC: CardioOncology State-of-the-Art Review.es_ES
dc.typereview articlees_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID38205010es_ES
dc.format.volume5es_ES
dc.format.number6es_ES
dc.format.page715es_ES
dc.identifier.doi10.1016/j.jaccao.2023.08.003es_ES
dc.description.peerreviewedSíes_ES
dc.identifier.e-issn2666-0873es_ES
dc.relation.publisherversion10.1016/j.jaccao.2023.08.003es_ES
dc.identifier.journalJACC. CardioOncologyes_ES
dc.repisalud.institucionCNICes_ES
dc.rights.accessRightsopen accesses_ES


Files in this item

Acceso Abierto
Thumbnail
Name:
Priorities in Cardio_Oncology ...
Size:
1.271Mb
Format:
PDF
Description:
Review
FilesOpen

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional